OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lai on the Role of Maintenance Therapy and Secondary Cytoreduction in Ovarian Cancer

October 12th 2021

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

Dr. Venkat on Treatment Considerations in Ovarian Cancer

October 11th 2021

Puja S. Venkat, MD, discusses treatment considerations for patients with ovarian cancer.

Dr. Ghobrial on the Key Objectives of the PROMISE Study in Multiple Myeloma

October 11th 2021

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Dr. Msaouel on Reducing Risk Factors for Renal Medullary Carcinoma With Exercise

October 11th 2021

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Dr. Jonasch on Pivotal Developments in the Treatment of RCC

October 11th 2021

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Dr. Zakharia on the Role of Seleno-L-Methionine in Previously Treated Advanced RCC

October 11th 2021

Yousef Zakharia, MD, discusses the role of seleno-L-methionine in previously treated advanced clear cell renal cell carcinoma.

Dr. McGregor Discusses Ongoing Trials in Non-Clear Cell RCC

October 11th 2021

Bradley McGregor, MD, discusses ongoing trials in patients with non-clear cell renal cell carcinoma (RCC).

Dr. McKay on the Outcomes of Landmark Trials in Frontline RCC

October 11th 2021

Rana R. McKay, MD, discusses the outcomes of landmark clinical trials in frontline renal cell carcinoma.

Dr. Zhang on the Key Objectives of the PDIGREE Trial in Advanced RCC

October 8th 2021

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Dr. Zarrabi on the Real-World Data With Axitinib/Pembrolizumab Vs Ipilimumab/Nivolumab in Clear Cell RCC

October 8th 2021

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Dr. Ahn on the Increased Understanding of Cholangiocarcinoma

October 8th 2021

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Dr. Baljevic on the Current Limitations of CAR T-Cell Therapy in Multiple Myeloma

October 8th 2021

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Dr. Popat on Mitigating Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 8th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Dr. Spaggiari on Surgical Interventions in CRC With Liver Metastases

October 7th 2021

Mario Spaggiari, MD, discusses surgical interventions in colorectal cancer with liver metastases.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 7th 2021

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Secord on Treatment Considerations in Platinum-Sensitive Ovarian Cancer

October 7th 2021

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.

Dr. Jamieson on Treatment Considerations in Myelofibrosis

October 7th 2021

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Dr. Jain on Advances With Surgery and Systemic Therapy in CRC With Liver Metastases

October 7th 2021

Shikha Jain, MD, FACP, discusses advances with surgical interventions and systemic therapies in colorectal cancer with liver metastases.

Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

October 7th 2021

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 6th 2021

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.